Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.

Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: A water containment apparatus includes a straight strut arrangement comprising a plurality of straight strut assemblies forming an alternating v-shape and inverted v-shape pattern; and a curved strut arrangement comprising a plurality of corner strut assemblies forming a desired curvature and connecting two straight strut arrangements to form a closed loop water containment system.

Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Abstract: Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.

Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: A method, system, apparatus, and/or device to creating a set of miniaturized electrode pillars. The method, system, apparatus, and/or device may include patterning a set of miniaturized electrode pillars on a substrate and coating the set of miniaturized electrode pillars with an interstitial filler disposed between the set of miniaturized electrode pillars. The interstitial filler may insulate the set of miniaturized electrode pillars from each other and bolster the set of miniaturized electrode pillars.

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: A restraint device for use with a vehicular straightening system includes an elongated tether that is connected to a restraining net along a first end, and an anchor connector along a second end. The anchor connector includes functionality for engaging the platform of the straightening system, and the restraining net includes a shape and size that is suitable for encompassing the fastening mechanism of the straightening system. A plurality of net connectors secure the restraining net about the fastening mechanism, and each of the tether, the restraining net and the connectors are constructed from materials having a high tensile strength for resisting a recoil force associated with a breakage of the fastening mechanism when a pulling force is applied thereon.

Abstract: The present invention relates to sheet material dispensing and cutting systems and boxes and related mechanisms and components, including methods of manufacture, methods of use, and related kits.

Abstract: A method, computer system, and computer program product for optimizing a number of robots for operation of a process at a target system. The method may include providing a plurality of available robots to carry out tasks in the process at the target system. The method may monitor the target system by carrying out the process or part of the process with a varying number of robots to determine the processor utilization whilst the robots are executing a varying number of tasks. The method may balance process constraints of the execution of the process with physical system constraints of the target system by measuring a relationship between a number of tasks at a transactional level and the processor utilization. The method may output the optimized number of robots to be allocated for the process or part of the process.

Abstract: A computing device includes a hardware switch that is activated when a primary Basic Input/Output System (BIOS) of a first BIOS chip of the device fails to load an Operating System (OS) image from an OS partition of a hard drive. The switch passes control to a backup BIOS that executes from a backup BIOS chip. The backup BIOS loads a recovery image from BIOS recovery partition of the hard drive, which causes a reflash application to execute from the recovery image. Reflash application obtains a recovery BIOS from the BIOS recovery partition of the hard drive, reflashes/writes the recovery BIOS onto the first BIOS chip and reboots the device. Following reboot of the device, recovery BIOS loads the OS image from the OS partition, and recovery BIOS becomes the primary BIOS on the first BIOS chip of the device.

Abstract: A liquid crystal waveguide (LCW) can include actively controlled incoupling of light into a LCW, such as by using a voltage-controlled electrode to actively vary a property of an LC material arranged to affect the incoupling of light into the LCW. Actively varying light incoupling into the LCW can be used, for example, such as for calibration or compensation or to provide closed-loop feedback such as to stabilize the amount of light into the LCW while accommodating or reducing sensitivity of the LCW to variations in one or more of: input laser light incidence angle, input laser wavelength, LCW or input laser temperature, input laser optical power level, or the like. This can advantageously help improve or maximize light incoupling efficiency, which can improve performance and robustness of the LCW under actual operating conditions. The LCW can be used for, among other things, beamsteering in in-plane and out-of-plane directions.

Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A/mu-opioid receptor or 5-HT2A/D1 and/or D2/mu-opioid receptor ligand.

Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, the compounds of Formula I: in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of central nervous system (CNS) diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Abstract: A leak test apparatus including a sleeve member having a first end and a second end and being configured to surround a portion of a transmission medium, a first retaining device configured to couple the first end of the sleeve member to a boundary fitting to which the transmission medium is coupled, and where the sleeve member is configured to contain a leak detection medium and effect a pressurization of the boundary fitting with the leak detection medium.